Expression of IL-17, IL-23 and Their Receptors in Minor Salivary Glands of Patients with  Primary Sjögren's Syndrome by Mieliauskaite, Diana et al.
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2012, Article ID 187258, 8 pages
doi:10.1155/2012/187258
Research Article
Expressionof IL-17, IL-23 and Their Receptors in Minor Salivary
Glandsof Patients with PrimarySj¨ ogren’s Syndrome
DianaMieliauskaite,IrenaDumalakiene,Rita Rugiene,andZygmunt Mackiewicz
Department of Experimental and Clinical Medicine, State Research Institute Center for Innovative Medicine,
Zygimantu Street 9, 01102 Vilnius, Lithuania
Correspondence should be addressed to Diana Mieliauskaite, diana.mieliauskaite@ekmi.vu.lt
Received 30 June 2011; Revised 28 September 2011; Accepted 28 September 2011
Academic Editor: Peter Szodoray
Copyright © 2012 Diana Mieliauskaite et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The main purpose of this study was to determine the expression of interleukins-17/-23 (ILs-17/-23) and receptors of interleu-
kins-17/-23 (IL-17R, IL-23R) in minor salivary glands (MSGs) of patients with primary Sj¨ ogren’s syndrome (pSS). Expression of
IL-17, IL-23 and receptors of IL-17/-23 was analyzed in MSGs from 25 patients with pSS, 25 patients with probable preclinical
pSS, and 25 patients with nonautoimmune sicca syndrome by immunohistochemistry. Comparison of the expression of IL-17,
IL-23 and receptors of IL-17, IL-23 in MSG of patients with pSS with probable preclinical pSS, and with nonautoimmune sicca
syndrome showed signiﬁcant diﬀerences between three groups. However, the expression of IL-17, IL-23 and receptors of IL-17/-23
in MSG was comparable in pSS and probable preclinical pSS patients. We did not ﬁnd correlation between the expression of IL-17
and IL-23 and of IL-17R and IL-23R in patients with pSS. These results demonstrate an involvement of IL-17/-23 system in the
early pSS pathogenesis.
1.Introduction
Primary Sj¨ ogren’s syndrome (pSS) is a systemic chronic
inﬂammatory autoimmune disorder that aﬀects secretory
organs. pSS is not only characterized by sicca syndrome
but also by extraglandular manifestations that reveal the
severity of this disorder. Patients with pSS also present broad
spectrum analytical features (cytopenias, hypergammaglob-
ulinemia, and cryoglobulins) and autoantibodies (antinu-
clear antibodies, anti-Ro/SSA, and anti-La/SSB antibodies).
Thus, the spectrum of the disease ranges widely from
minimal local symptoms of the eyes and oral mucosa to
systemic involvement and the development of malignant
lymphoma, the latter being the most worrisome complica-
tion of primary Sj¨ ogren’s syndrome [1–8]. Pathophysiology
of Sj¨ ogren’s syndrome is not yet fully understood. Cytokines
play a central role in the regulation of immunity and are
often found to be deregulated in autoimmune diseases [9].
Recently, much attention has been focused on the relation-
ship between innate responses and subsequent activation
of speciﬁc adaptive immunity in an attempt to understand
subsequent immune dysregulation. With the identiﬁcation
of CD4+ Th17 cell population, which initially challenged the
long-standing Th1/Th2 paradigm, severalof these important
relationshipsbetweeninnateandadaptiveimmunityarenow
being uncovered. A subset of CD4+ memory T cells are
characterizedbytheiruniqueabilitytosecreteinterleukin-17
(IL-17) family cytokines. Importantly, Th17 cells appear to
be intimately involved in autoimmunity. As mature memory
cells, Th17 cell survival and maintenance appear to be
dependent on IL-23 [9–16].
The main purpose of this study was to determine the
expression of interleukins-17/-23 and receptors of inter-
leukins-17/-23 (IL-17R, IL-23R) focusing on autoimmune
epithelitis in patients with primary Sj¨ ogren’s syndrome. We
set tasks to investigate a relationship between expression of
IL-17andIL-23inpatientswithprimarySj¨ ogren’ssyndrome.
2.MaterialandMethods
2.1. Patients. Participants of the study were selected from
patients seen at the State Research Institute Center for
Innovative Medicine: 25 patients with pSS who meet the
American-European criteria for primary SS, 25 patients with2 Clinical and Developmental Immunology
Table 1: Clinical and serologic characteristics of the patients.
Variable pSS (n = 25) Probable preclinical pSS
(n = 25)
Nonautoimmune sicca syndrome
(n = 25)
Age, mean (s.d) 59.6 (11.9) 58.4 (13.4) 63.1 (10.1)
Ocular symptoms, n (%) 25 (100) 0 (0) 25 (100)
Oral symptoms, n (%) 25 (100) 0 (0) 25 (100)
Schirmer I test, ≤5mm/5min., n (%) 25 (100) 0 (0) 25 (100)
Unstimulated salivary ﬂow rate,
≤1.5mL/15min., n (%) 25 (100) 0 (0) 25 (100)
Salivary secretion, mean (s.d) 1.0 (0.22) 2.1 (0.4) 1.4 (0.17)
Histopathology, focus score ≥1, n (%) 25 (100) 20 (80) 0 (0)
Salivary gland enlargement, n (%) 5 (20) 0 (0) 0 (0)
Arthralgias, n (%) 18 (72) 15 (60) 14 (56)
Raynaud phenomenon, n (%) 3 (12) 1 (4) 0 (0)
Cutaneous vasculitis, n (%) 1 (4) 0 (0) 0 (0)
Pulmonary involvement, n (%) 3 (12) 0 (0) 0 (0)
Renal involvement, n (%) 0 (0) 0 (0) 0 (0)
Fatigue, n (%) 17 (68) 19 (76) 0 (0)
ESR, ↑, n (%) 7 (28) 12 (48) 0 (0)
Leucopenia, n (%) 6 (24) 8 (32) 0 (0)
Anemia, n (%) 8 (32) 6 (24) 0 (0)
RF, >15kU/I, n (%) 25 (100) 25 (100) 25 (100)
ANA, >1:40, n (%) 25 (100) 25 (100) 25 (100)
ACA, negative, n (%) 25 (100) 25 (100) 25 (100)
Anti-dsDNA, negative, n (%) 25 (100) 25 (100) 25 (100)
Anti-Scl-70, negative, n (%) 25 (100) 25 (100) 25 (100)
Anti-Sm, negative, n (%) 25 (100) 25 (100) 25 (100)
Anti-Ro/SSA, n (%) 21(84) 23 (92) 0 (0)
Anti-La/SSB, n (%) 0 (0) 0 (0) 0 (0)
Both anti-Ro/SSA and anti-La/SSB, n (%) 4 (16) 2 (8) 0 (0)
probablepreclinicalpSSwhodidnotmetfullytheAmerican-
European criteria for primary SS, and 25 patients with
nonautoimmune sicca syndrome. A new international con-
sensus for Sj¨ ogren’s syndrome diagnosis requires objective
signs and symptoms of dryness including a characteristic
appearance of a biopsy sample from a minor salivary gland
orautoantibodysuchasanti-SSA/Roor/andanti-SSB/La[3].
Symptoms and signs of Sj¨ ogren’syndrome are subtle
and can be intermittent or nonspeciﬁc [4, 6, 17–20]. Our
experience has revealed that about one-third of patients
with pSS had extraglandular manifestations before the onset
of sicca ocular and oral symptoms and signs including
mild asymptomatic hematologic manifestations (anemia,
leucopenia, and increased erythrocyte sedimentation rate).
It has been estimated that these signs are present for a
mean of seven years before primary Sj¨ ogren’s is properly
diagnosed. Patients who had mild asymptomatic hemato-
logic abnormalities (anemia, and leucopenia, increased ery-
throcyte sedimentation rate), positive anti-SSA/Ro or/and
anti-SSB/La, and negative serology for hepatitis C, EBV,
cytomegalovirus, and human immunodeﬁciency virus were
included in the probable preclinical pSS group. All patients
underwent an extensive medical examination. Following the
initial evaluation by a rheumatologist, each patient was
referred to Sj¨ ogren’s syndrome specialists for a review of
his/her medical history, an oral and an ocular examination,
Schirmer’s I test, unstimulated salivary ﬂow rate, and a
labial gland biopsy. Also, all patients underwent extensive
serologic evaluations which included test for the presence
of rheumatoid factor (RF), antinuclear antibodies (ANA),
anticentromereantibodies,anti-double-strandedDNA,anti-
Scl-70, anti-Sm, anti-SSA/Ro, and anti-SSB/La (Table 1).
Patients of all groups had negative serology for hepatitis
C, EBV, cytomegalovirus, and human immunodeﬁciency
virus.
Informed and written consent was obtained from all
patients who participated in this study. The study has been
approved by the Lithuanian Bioethics Committee (2009-06-
03, No.: 158200-6-061-15).Clinical and Developmental Immunology 3
2.2. Labial Salivary Gland Biopsy. Labial salivary gland biop-
sies were performed on patients by the oral medicine
specialist. A local anesthetic was injected into the lower
lip followed by a small incision to the right or left of
the lip midline. Five or six minor salivary gland lobules
were harvested and placed into formalin ﬁxative. Standard
paraﬃn preparations were prepared, sectioned, and stained
with hematoxylin and eosin. The slides were examined for
the presence of lymphocytic inﬁltrates by 2 board-certiﬁed
pathologists.
2.3. Immunohistochemical Staining. Biopsy specimens from
the lips of patients were placed in 10% phosphate-buﬀered
formalin for 24 hours. Fixed tissues were embedded in
paraﬃn and sectioned at 4μm thick sections with Microm
microtome. 4μmt i s s u es e c t i o n sw e r ed e p a r a ﬃnized by
immersion in xylene followed by dehydratation in ethanol.
Antigen retrieval was performed in 0.01M sodium citrate
buﬀe r ,p H6 . 0 ,a t+ 9 8 ◦C for half an hour in Milestone
histoprocessor or with 0.05% trypsin solution (pH 7.8) for
2 0m i n u t e sa t3 7 ◦C., followed by cooling down at +22◦C
for 30min. Endogenous peroxidase was blocked with 0.3%
H2O2 in methanol for 30 minutes at +22◦C. Following a 5-
minute wash with PBS, sections were incubated at +22◦Cf o r
30 minutes with primary antibody at the room temperature.
Primary antibodies were used: rabbit anti-human IL-17
(H-132) polyclonal antibody, 2μg/mL (Santa Cruz Biotech-
nology, Inc, Santa Cruz, CA, USA); goat anti-human IL-17
RD/SEF receptor polyclonal IgG, 4μg/mL (R&D Systems,
Minneapolis, MN, USA); mouse anti-human IL-23 (p19)
monoclonal IgG1, κ,4 μg/mL (BioLegend, San Diego, CA,
USA); goat anti-human IL-23 receptor polyclonal antibody,
4μg/mL (Capralogics, Inc. Hardwick, MA, USA).
Incubationwithappropriatebiotinylatedsecondaryanti-
bodies: rabbit anti-goat, horse anti-mouse, or goat anti-
rabbit, all from the VECTASTAIN ABC kit, 1:200 (Vector
Laboratories, Burlingame, CA, USA), was performed at
+22◦C for half an hour and was used following man-
ufacturer’s instructions. All incubations were performed
in humid atmosphere. The staining was developed by
using diaminobenzidine substrate (Vector Laboratories,
Burlingame, CA, USA), and counterstaining was performed
with hematoxylin (Merck, Darmstadt, Germany), followed
by mounting in HistoGel (Lab. Storage Systems Inc., St.
Peters, MO, USA). Slides were rinsed in PBS 2 × 5m i n u t e s
after each step.
2.4. Evaluation of the Results. Semiquantitative microscopic
assessmentofimmunohistochemicalstainingwasperformed
in light microscope Olympus BX51 under ×400 (high-power
ﬁelds)scoring5randomﬁeldsin10randomsimilarlystained
slides using four grades: “0” = no immunoreactivity; “1” =
low immunoreactivity; “2” = moderate immunoreactivity;
“3” = high immunoreactivity. In every slide were separately
scored: (1) acini; (2) glandular ducts; (3) intraglandular
interstitium; (4) blood vessels; (5) inﬁltrating inﬂammatory
cells. The immunoreactivity grades of IL-17, IL-23, IL-17R,
and IL-23R in the separate localizations sum is a total
expression of mentioned interleukins and their receptors.
Theoretically, maximum score could reach the value of
15. Practically, such a value never occurred in this study.
Two histologists evaluated the results of histological and
immunohistochemical staining independently using this
predeﬁned and a very simple scoring system leading to very
similar readouts and followed by a consensus session.
2.5. Statistical Analysis. All values presented are the mean ±
SD. Statistical diﬀerences were analyzed with the Mann-
Whitney, Kruskal-Wallis tests using standard program SPSS
19.0. P values less than 0.05 were considered signiﬁcant.
3. Results
IL-17, IL-23, IL-17R, and IL-23R were detected in glandular
ducts (d), acini (a), blood vessels (bl v), intraglandular
interstitium (i), inﬁltrating inﬂammatory cells (ly) of minor
salivary glands (MSGs) of patients with pSS (n = 25), prob-
able preclinical pSS (n = 25), and nonautoimmune sicca
syndrome (n = 25). Representative photomicrographs of the
expression patterns in patients with pSS, probable preclinical
pSS, and nonautoimmune sicca syndrome are shown in
ﬁgures (Figures 1 and 2).
Assessment of the total expression of IL-17, IL-23
and receptors of IL-17, IL-23 in MSGs of patients with
pSS, probable preclinical pSS, and nonautoimmune sicca
syndrome and comparison of the total expression of IL-17,
IL-23 and receptors of IL-17, IL-23 between three groups
showed signiﬁcant diﬀerences (P<0.05) (Tables 2 and 3).
The mean total expression of IL-17, IL-23 and receptors
of IL-17, IL-23 was increased in MSGs of pSS patients
compared with nonautoimmune sicca syndrome patients
(P<0.05). However, the total expression of IL-17, IL-23 and
receptors of IL-17, IL-23 in MSGs of pSS was comparable to
probable preclinical pSS patients. Comparison of the total
expression of IL-17, IL-23, and IL-17R between probable
preclinicalpSSandnonautoimmunesiccasyndromepatients
showed signiﬁcant diﬀerences. Furthermore, the highest
expression of IL-17, IL-23 was revealed in glandular ducts
and inﬂammatory cells of patients with pSS and probable
preclinical pSS. Expression of IL-17R in glandular ducts was
increased in MSGs of pSS (P<0.05) and was comparable in
the glandular ducts of patients with probable preclinical pSS
and nonautoimmune sicca syndrome.
The total expression of IL-23 was increased in MGS
of pSS patients compared with nonautoimmune sicca syn-
drome patients. We found the highest expression of IL-23 in
glandular ducts and acini of patients with pSS and probable
preclinical pSS. The IL-23 expression in blood vessels,
intraglandular interstitium, and inﬁltrating inﬂammatory
cells of minor salivary glands was comparable in three
groups. Our study revealed that the total expression of
IL-23R was signiﬁcantly higher compared with the total
expression of IL-23 in MSGs of patients with probable
preclinical pSS. The total expression of IL-23R and of IL-23R
in glandular ducts, acini, intraglandular interstitium, and
inﬁltrating inﬂammatory cells was comparable in pSS and4 Clinical and Developmental Immunology
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Figure 1: Expression of IL-17 and IL-17R in minor salivary glands of patients with pSS, probable preclinical pSS, and nonautoimmune
sicca syndrome. IL-17: (a) pSS, (b) probable preclinical pSS, (c) nonautoimmune sicca syndrome. IL-17R: (d) pSS, (e) probable preclinical
pSS, (f) nonautoimmune sicca syndrome, (g) negative staining control. Counterstained with hematoxylin. Original magniﬁcation ×400.
Abbreviations: A: acinus, Adip-adipocytes, Bv: blood vessel, D: ductus, and Ly: lymphocyte inﬁltration.Clinical and Developmental Immunology 5
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Figure 2: Expression of IL-23 and IL-23R in minor salivary glands of patients with pSS, probable preclinical pSS and nonautoimmune
sicca syndrome. IL-23: (a) pSS, (b) probable preclinical pSS, (c) nonautoimmune sicca syndrome. IL-23R: (d) pSS, (e) probable preclinical
pSS, (f) nonautoimmune sicca syndrome, (g) negative staining control. Counterstained with hematoxylin. Original magniﬁcation ×400.
Abbreviations: A: acinus, Bv: blood vessel, D: ductus, and Ly: lymphocyte inﬁltration.6 Clinical and Developmental Immunology
Table 2: Expression (grades) of IL-17 and IL-17R in minor salivary glands of patients with primary Sj¨ ogren’s syndrome (pSS), with probable
preclinical primary Sj¨ ogren’s syndrome (probable preclinical pSS), and with nonautoimmune sicca syndrome: ducti (d), acini (a), blood
vessels (bl v), interstitium (i), lymphocytes (ly)] [mean ± SD, median (M)].
Variable
pSS Probable preclinical pSS Nonautoimmune sicca syndrome
Mean ± SD M Mean ± SD M Mean ± SD M
IL-17 4.6 ±1.38
∗,2,3 5.0 4.32 ±1.31 4.0 3.8 ±1.15 3.0
IL-17 a 0.88 ±0.33
∗,2,3 1.0 0.96 ±0.54 1.0 0.56 ±0.51 1.0
IL-17 d 1.68 ±0.48∗,2 2.0 1.44 ±0.51 1.0 1.20 ±0.41 1.0
IL-17 i 0.60 ±0.50∗,1,2 1.0 0.16 ±0.37 0.0 0.12 ±0.33 0.0
IL-17 bl v 0.32 ±0.56∗,1,3 0.0 0.60 ±0.50 1.0 0.20 ±0.41 0.0
IL-17 ly 1.16 ± 0.372,3 1.0 1.20 ±0.41 1.0 1.00 ±0.00 1.0
IL-17R 4.68 ±1.84∗,2,3 5.0 4.44 ±1.89 4.0 3.08 ±1.68 3.0
IL-17R a 0.88 ±0.33∗,2,3 1.0 0.96 ±0.45 1.0 0.56 ±0.51 1.0
IL-17R d 1.68 ±0.48∗,1,2 2.0 1.32 ±0.48 1.0 1.20 ±0.41 1.0
IL-17R i 0.24 ±0.44 0.0 0.44 ±0.51 0.0 0.20 ±0.41 0.0
IL-17R bl v 1.04 ±0.79∗,2,3 1.0 0.84 ±0.55 1.0 0.48 ±0.51 0.0
IL-17R ly 0.84 ±0.37 1.0 0.88 ±0.44 1.0 0.64 ±0.49 1.0
∗P < 0.05, comparison between all groups (Kruskal-Wallis test);
1P<0.05, comparison between patients with pSS and probable preclinical pSS (Mann-Whitney U test);
2P<0.05, comparison between patients with pSS and nonautoimmune sicca syndrome (Mann-Whitney U test);
3P<0.05, comparison between patients with probable preclinical pSS and nonautoimmune sicca syndrome (Mann-Whitney U test).
Table 3: Expression (grades) IL-23 and IL-23R in minor salivary glands of patients with primary Sj¨ ogren’s syndrome (pSS), with probable
preclinical primary Sj¨ ogren’s syndrome (probable preclinical pSS), and with nonautoimmune sicca syndrome: ducti (d), acini (a), blood
vessels (bl v), interstitium (i), lymphocytes (ly)], [mean ± SD, median (M)].
Variable
pSS Probable preclinical pSS Nonautoimmune sicca syndrome
Mean ± SD M Mean ± SD M Mean ± SD M
IL-23 4.08 ±1.75∗,2 4.0 3.32 ±1.35 4.0 2.68 ±1.68 3.0
IL-23 a 0.96 ±0.54∗,2,3 1.0 0.84 ±0.47 1.0 0.52 ±0.51 1.0
IL-23 d 1.64 ±0.49∗,2,3 2.0 1.44 ±0.51 1.0 1.08 ±0.49 1.0
IL-23 i 0.28 ±0.46 0.0 0.2 ± 0.41 0.0 0.32 ±0.48 0.0
IL-23 bl v 0.24 ±0.44 0.0 0.16 ±0.37 0.0 0.16 ±0.37 0.0
IL-23 ly 0.88 ±0.60 1.0 0.68 ±0.48 1.0 0.64 ±0.57 1.0
IL-23R 4.28 ±1.97∗,2,3 4.0 4.52 ±1.96 5.0 2.76 ±1.79 3.0
IL-23R a 0.96 ±0.54∗,2,3 1.0 0.80 ±0.41 1.0 0.52 ±0.51 1.0
IL-23R d 1.52 ±0.51∗,2,3 2.0 1.36 ±0.49 1.0 1.0 ±0.41 1.0
IL-23R i 0.48 ±0.51∗,3 0.0 0.76 ±0.52 1.0 0.48 ±0.51 0.0
IL-23R bl v 0.44 ±0.51 0.0 0.72 ±0.54 1.0 0.20 ±0.41 0.0
IL-23R ly 0.88 ±0.44∗,2,3 1.0 0.88 ±0.44 1.0 0.56 ±0.51 1.0
∗P < 0,05, comparison between all groups (Kruskal-Wallis test);
1P<0,05, comparison between patients with pSS and probable preclinical pSS (Mann-Whitney U test);
2P<0,05, comparison between patients with pSS and nonautoimmune sicca syndrome (Mann-Whitney U test);
3P<0,05, comparison between patients with probable preclinical pSS and nonautoimmune sicca syndrome (Mann-Whitney U test).
probable preclinical pSS patients. Furthermore, we found
thatthetotalexpressionofIL-23RandofIL-23Ringlandular
ducts, acini, intraglandular interstitium, and inﬁltrating
inﬂammatorycellswassigniﬁcantlyhigherinpSSandproba-
ble preclinical pSS patients compared with nonautoimmune
sicca syndrome patients.
Expression of IL-17/IL-23 and IL-17R/IL-23R signiﬁ-
cantly correlated in minor salivary glands of patients with
probable preclinical pSS (accordingly, r = 0.683, P<0.001
and r = 0.406, P = 0.044) and nonautoimmune sicca
syndrome patients (accordingly, r = 0.740, P<0.001 and
r = 0.506, P = 0.010). We did not ﬁnd correlation between
expression of IL-17R and IL-23R in patients with pSS (r =
0.181; P = 0.386).
4. Discussion
In this study, we sought to determine the expres-
sion of interleukins-17/-23 (IL-17/-23) and receptors ofClinical and Developmental Immunology 7
interleukins-17/-23 (IL-17R, IL-23R) in minor salivary
glands (MSGs) of patients with primary Sj¨ ogren’s syn-
drome (pSS), with probable preclinical pSS, and with
nonautoimmune sicca syndrome. Patients who had mild
asymptomatic hematologic abnormalities (anemia, leucope-
nia, and increased erythrocyte sedimentation rate), positive
anti-SSA/Ro or/and anti-SSB/La, and negative serology for
hepatitis C, EBV, cytomegalovirus, and human immunod-
eﬁciency virus were included in the probable preclinical
pSS group. Among the antinuclear autoantigens targets, the
ribonucleoprotein particles (Ro/SSA and La/SSB) have a
prominentroleinpSSdiagnosisandsystemicactivity[6,17].
Cytokine-mediated immunity plays a substantial role in
the pathogenesis of various autoimmune diseases including
primary Sj¨ ogren’s syndrome. Dysregulation of the cytokine
network contributes to both systemic and exocrine man-
ifestations of SS [9]. Recently some studies have added
primary Sj¨ ogren’s syndrome to the rapidly expanding list of
autoimmune diseases (e.g., multiple sclerosis, systemic lupus
erythematosus, rheumatoid arthritis, and psoriasis) in which
cytokines IL-17 and IL-23 are now implicated [12, 21–27].
Besides being produced by Th17 cells, IL-17A is also
produced by a variety of cell types, including NK cells,
neutrophils, and eosinophils. Thus, IL-17 is an eﬀector
cytokine that is produced by cells of both the innate and
theadaptiveimmunesystems,suggestingabridgingfunction
of this type of immunity between innate and adaptive
immune responses. IL-17A has proinﬂammatory properties
and act on broad range of cell types to induce expression
of cytokines, chemokines, and metalloproteinases. IL-17 was
reported to be a factor that contributes to the formation
of germinal centers (GCs) of lymph follicles retaining B
cells within GCs an enhancing through modulation of
chemokine activity. The IL-17 receptors constitute a distinct
family of cytokine receptors. IL-17RA and IL-17RC are the
receptors for IL-17A and IL-17F. IL-17RA not only conveys
proinﬂammatory IL-17 eﬀects, but also contributes in IL-
25 signaling. IL-17RA binds IL-17A with higher aﬃnity
compared with IL-17F. IL-17RA is not only highly expressed
on hematopoietic cells, but also at lower levels on endothelial
cells, epithelial cells, osteoblasts, and ﬁbroblasts [10, 15].
Recent studies revealed that IL-23, not IL-12, is regarded
as a crucial cytokine for the pathogenesis of autoimmune
diseases. IL-23 plays a key role in the development of
pathogenetic Th17 cells that produce the cytokine IL-17 and
ﬁnally contribute to hyperproduction of IL-17 and other
cytokines. IL-23 is expressed predominantly by activated
dendritic and phagocytic cells. IL-12 and IL-23 share a
common p40 subunit binding to common IL-12 receptor
(IL-23R). IL-23R is expressed on activated/memory T cells,
T-cell clones, and natural killer cell lines in human. IL-23R
has now been proposed as a common genetic marker for a
variety of autoimmune diseases [28].
Comparison of the total expression of IL-17 and IL-
17R in minor salivary glands between three groups showed
signiﬁcant diﬀerences. However, the total expression of
IL-17 and IL-17R in MSGs of pSS was comparable to
probable preclinical pSS patients. The highest expression
of IL-17 was revealed in glandular ducts and inﬂammatory
cells of patients with pSS and probable preclinical pSS.
Resent study also revealed that the staining of the IL-17
and IL-23 appeared localized to lymphocytic inﬁltrates and
ductal cells, with less staining occurring in acini. Another
resent study showed that ageing induces speciﬁc changes in
lacrimal-keratoconjunctivitis in CD25KO mice, with a mix
of Th1 and Th17 cytokines, and that the peak severity of
corneal epithelial disease corresponded to the peak of IL-17
expression [29].
The expression of IL-17R in glandular ducts was sig-
niﬁcantly higher in pSS patients compared with probable
preclinical pSS patients, but the expression of IL-17R in acini
of pSS patients was comparable to probable preclinical pSS
patients. These results suggest that autoimmune inﬂamma-
tion may appear in salivary glands before sicca symptoms
and signs in patients with probable pSS.
The total expression IL-23 and IL-23R in minor salivary
glands of pSS was comparable to probable preclinical pSS
patients. In contrast to our results, before-mentioned study
revealed that IL-17 expression appeared stronger and more
widely distributed than IL-23 expression in pSS patients
[12]. We suppose that this contrast might be explained
by diﬀerent sizes of study groups. We found the highest
expression of IL-23 in glandular ducts and acini of patients
with pSS and probable preclinical pSS. Our study revealed
that the total expression of IL-23R was signiﬁcantly higher
compared with the total expression of IL-23 in MSGs of
patients with probable preclinical pSS. The total expression
of IL-23R and expression of IL-23R in glandular ducts, acini,
intraglandular interstitium, and inﬁltrating inﬂammatory
cells was comparable in pSS and probable preclinical pSS
patients. These results may demonstrate an inﬂuential role
of IL-23R in the onset of autoimmune epithelitis. Future
investigations need to take these data into consideration in
designing studies to examine eﬀects of IL-23R. Furthermore,
IL-23R has now been proposed as a common genetic marker
for a variety of autoimmune diseases [28].
The expression of IL-17/IL-23 and IL-17R/IL-23R sig-
niﬁcantly correlated in minor salivary glands of patients
with probable preclinical pSS and nonautoimmune sicca
syndrome patients. We did not ﬁnd correlation between
expression of IL-17R and IL-23R in patients with pSS. These
data reﬂect that cytokines networks may contribute to the
pathogenesis of SS in various and separate ways.
We speculate that the particular expression of interleu-
kins-17/-23 and their receptors may reﬂect ongoing autoim-
mune inﬂammation in various target organs and suggest a
role for these interleukins and their receptors in the early SS
stage.
5. Conclusion
These results demonstrate an involvement of interleukin-
17/-23 in the early Sj¨ ogren’s syndrome pathogenesis.
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